NCT06696183
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06696183 |
| Title | Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment (SEQUENCE) |
| Acronym | SEQUENCE |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Technische Universität Dresden |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | DEU |
CKB BOOST